MRC1 and neoplasm: Zang et al. developed a CD206 (macrophage mannose receptor 1) targeting nanoparticle modified with mannose, which has TAMs-targeted capacity, effectively depleted TAMs and eventually restrained tumor growth without eliciting systemic effects [29].